Suvretta Capital Management LLC Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Suvretta Capital Management LLC cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,019,000 shares of the biopharmaceutical company’s stock after selling 259,000 shares during the period. Ultragenyx Pharmaceutical makes up approximately 1.6% of Suvretta Capital Management LLC’s holdings, making the stock its 22nd largest holding. Suvretta Capital Management LLC owned about 2.09% of Ultragenyx Pharmaceutical worth $60,732,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of RARE. Wellington Management Group LLP boosted its stake in shares of Ultragenyx Pharmaceutical by 3.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,945,129 shares of the biopharmaceutical company’s stock worth $58,509,000 after acquiring an additional 73,309 shares in the last quarter. Comerica Bank increased its stake in Ultragenyx Pharmaceutical by 68.6% in the 3rd quarter. Comerica Bank now owns 83,711 shares of the biopharmaceutical company’s stock valued at $2,518,000 after purchasing an additional 34,051 shares in the last quarter. F m Investments LLC raised its holdings in Ultragenyx Pharmaceutical by 4.5% during the third quarter. F m Investments LLC now owns 61,753 shares of the biopharmaceutical company’s stock worth $1,858,000 after purchasing an additional 2,651 shares during the last quarter. Entropy Technologies LP raised its holdings in Ultragenyx Pharmaceutical by 77.0% during the third quarter. Entropy Technologies LP now owns 20,064 shares of the biopharmaceutical company’s stock worth $604,000 after purchasing an additional 8,728 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Ultragenyx Pharmaceutical by 9.8% during the third quarter. Invesco Ltd. now owns 794,849 shares of the biopharmaceutical company’s stock worth $23,909,000 after purchasing an additional 70,734 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RARE. Wells Fargo & Company dropped their price target on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research report on Tuesday, December 30th. JPMorgan Chase & Co. lowered their price objective on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research note on Thursday. Bank of America dropped their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a report on Friday, January 2nd. Barclays reduced their price target on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Finally, HC Wainwright reduced their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Sixteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $65.76.

Ultragenyx Pharmaceutical Trading Down 1.7%

Ultragenyx Pharmaceutical stock opened at $21.34 on Friday. The stock has a 50-day moving average price of $23.01 and a 200 day moving average price of $28.83. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.41 and a 52 week high of $42.37. The stock has a market cap of $2.06 billion, a PE ratio of -3.65 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The firm had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. During the same quarter last year, the company posted ($1.39) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% on a year-over-year basis. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Erik Harris sold 10,539 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $240,289.20. Following the completion of the sale, the executive vice president directly owned 89,515 shares of the company’s stock, valued at approximately $2,040,942. The trade was a 10.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Richard Pinion sold 10,029 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $228,661.20. Following the completion of the transaction, the insider owned 110,026 shares of the company’s stock, valued at $2,508,592.80. This trade represents a 8.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 104,958 shares of company stock valued at $2,394,858. 5.50% of the stock is currently owned by insiders.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.